BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Everest Medicines receives full payment from Gilead for Trodelvy transaction, boosting cash reserves

"With the full upfront payment and other reimbursement from Gilead, we now have an even stronger balance sheet to advance development of products in our co...

March 28, 2023 | News

WuXi Biologics Reports Remarkable 2022 Annual Results

2022 Financial Highlights Revenue: The Group's revenue increased to RMB15,268.7 million with an increase of 48.4% y-o-y. The increase was...

March 23, 2023 | News

Jacobio Collaborates to Evaluate JAB-BX102 with KEYTRUDA® for Cancer Patients.

Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combinatio...

March 22, 2023 | News

Agilis Robotics has begun its first trial in mainland China, marking a significant advancement in the country's robotic endoscopic surgery.

The Agilis Robotics system is designed to make endoscopic and endoluminal surgery easier, faster, and more precise. The ultra-thin instruments ar...

March 20, 2023 | News

Connect Biopharma's CBP-201 demonstrates swift relief of Atopic Dermatitis symptoms in pivotal study in China

Stage 1 of ongoing 52-week China pivotal AD trial met primary and secondary endpoints No efficacy plateau at Week 16 In the study “CBP-201, a n...

March 20, 2023 | News

Keymed Biosciences Advancing Clinical Progress and Global Collaboration

Development of Innovative and Differentiated Pipelines Core Product CM310 (IL-4Rα antibody): Initiated Phase III registrational cl...

March 18, 2023 | News

China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval

On December 22, 2022, Likang submitted an IND application for LK101 Injection to NMPA, and received application shortly after. LK101 Injection, the fi...

March 17, 2023 | News

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

ADC drugs have the advantages of highly specific targeting of antibody and anti cancer activity of cytotoxin. ADC shave developed rapidly as tumor therapeu...

March 16, 2023 | News

FDA approves Abbisko Therapeutics' Pimicotinib for Phase III clinical trial

This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib （ABSK021）was granted BTD by FDA and CDE, discovered a...

March 16, 2023 | News

Ark Biopharmaceutical and Calibr collaborate on potential first-in-class drug for respiratory diseases

Ark Biopharmaceutical will lead development activities for AK0705 with the goal of initiating clinical studies in 2024. Calibr will continue to collabor...

March 16, 2023 | News

Mabwell begins first human trial of iron-regulating drug 9MW3011

The study (CTR20230046) is a phase 1, single center, randomized, double-blind，placebo-controlled, ascending dose study to evaluate the safety, ...

March 15, 2023 | News

Simcere Zaiming partners with Merck for SIM0235 clinical trial in advanced tumors and lymphoma

Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an in...

March 15, 2023 | News

Antengene's ATG-022 Phase I CLINCH Trial for Solid Tumor Treatment Receives IND Approval in China

- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Assoc...

March 14, 2023 | News

Everest Medicines' Partner Calliditas Reports Positive Phase 3 Results for Nefecon in IgA Nephropathy Trial

The trial met its primary endpoint with Nefecon demonstrating a highly statistically significant benefit over placebo (p value < 0.0001) in estimated gl...

March 14, 2023 | News

Stay Connected